NRAS and acute myeloid leukemia: Of the remaining commonly mutated genes in NK-AML, neither mutations in NRAS (5-year EFS: 61%; CI: 43–74%), PTPN11 (5-year EFS: 57%; CI: 43–59%), nor TET2 (5-year EFS: 43%; CI: 43–74%), were associated with any significant differences in prognosis (Figures S1 and S2).